LSD Analogues for Health & Longevity

Evidence Review created on 08/05/2026 using AI4L / Opus 5

Also known as: Lysergamides, LSD Prodrugs, 1P-LSD, 1cP-LSD, ALD-52, 1B-LSD, 1V-LSD, 1D-LSD, 1T-LSD, 1S-LSD, 1F-LSD, 1H-LSD, 1DD-LSD, AL-LAD, ETH-LAD, LSZ, LSM-775, MIPLA, DDH-LSD, 2-Br-LSD, BOL-148, JRT

Motivation

LSD analogues are laboratory-made relatives of LSD (lysergic acid diethylamide). Most sold today are chemical shells: the body strips the added piece away and releases plain LSD. A smaller and newer set is built in the opposite direction, redesigned to keep the mood and brain-remodelling effects while removing the visions. Interest in the first group grew mainly because the added piece often places them outside the drug laws written for LSD.

The family now runs to dozens of compounds, sold on paper blotters and in dropper bottles under names that change every time a country closes a legal gap. Alongside them sits a much smaller group of redesigned molecules that pharmaceutical companies are developing as prescription candidates. Most health-oriented interest sits in repeated tiny doses taken for mood and mental sharpness, and in whether the redesigned molecules aid brain cell growth into later life. Almost everything known about either group comes from chemistry benches, animal work, and forensic casework, not human treatment studies.

This review examines what is documented about LSD analogues: how they behave once swallowed, which benefits and harms have actually been observed, how they are dosed, sourced, and monitored, and where the evidence runs out.

Benefits - Risks - Protocol - Conclusion

Grokipedia

Lysergamides

The site’s dedicated article for the analogue class as a whole, setting out the shared ergoline chemistry (ergolines are the ring compounds of the ergot fungus that LSD itself derives from), the receptor pharmacology, and the notable members alongside the parent compound they derive from. It is the more useful entry point than any single-compound page because it treats the whole family at once and maps the jurisdiction-by-jurisdiction legal position that drives the market for these substances.

Examine

LSD

Examine has no page for any LSD analogue; this entry covers the parent compound that the prodrug analogues release. It is useful mainly as a neutral summary of the preliminary human evidence for the molecule that those analogues actually deliver.

ConsumerLab

No ConsumerLab article exists for LSD analogues. ConsumerLab tests dietary supplements sold through retail channels and does not cover controlled substances or unscheduled research chemicals, neither of which enters the supplement supply chain it audits.

Systematic Reviews

Systematic reviews and meta-analyses bearing on LSD analogues, the non-hallucinogenic branch of the class, and the safety profile of the molecule the prodrug analogues release.

Lysergic Acid Amide (LSA), an LSD Analog: Systematic Review of Pharmacological Effects, Adverse Outcomes, and Therapeutic Potentials - Castro et al., 2025

The only systematic review addressing a named LSD analogue on its own terms, covering seventeen studies with original human data. It reports euphoria, hallucinations, nausea, and anxiety as the typical effect profile, documents psychosis, hypertension (high blood pressure) and hospitalisation as severe outcomes, and identifies dose variability and online misinformation as the dominant risk amplifiers — the same two failure modes that dominate the synthetic analogue market.
Non-hallucinogenic psychedelics for mood and anxiety disorders: A systematic review - Chen et al., 2025

Synthesises the entire published evidence base for the redesigned, non-hallucinogenic branch of this class and finds it consists of five animal studies plus a single human case report. It is the most direct available check on how far the therapeutic claims for compounds such as 2-Br-LSD and JRT currently outrun their evidence.
Side effects of microdosing lysergic acid diethylamide and psilocybin: A systematic review of potential physiological and psychiatric outcomes - Modzelewski et al., 2025

Pools 31 studies on the low-dose regimens for which prodrug analogues are most often purchased, grading 15 of them as higher-quality laboratory work. Side effects were dose-dependent, mild, and short-lived, with raised blood pressure, anxiety, and cognitive impairment the most common — a directly transferable safety picture, since the analogues deliver the same molecule.
Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis - Hinkle et al., 2024

Analyses 214 studies and 3,504 participants to produce the best current estimate of serious harm at full doses: none in healthy participants, roughly 4% in participants with pre-existing neuropsychiatric conditions. It also documents that only about a quarter of modern studies assessed adverse events systematically, which bounds how much reassurance the low figures can carry.
Psychedelic-induced hypomania and mania: a systematic review and meta-analysis - Eskinazi et al., 2026

The most recent quantitative synthesis of the mood-switching risk that determines who should be excluded from this class of compound altogether. It is the key counterweight to the benefit case, because the exclusion it supports removes a population that would otherwise be among the most motivated users.

Mechanism of Action

LSD analogues are not one pharmacological thing. They divide into three groups whose mechanisms have almost nothing in common beyond a shared ergoline skeleton — the four-ring core found in alkaloids of the ergot fungus Claviceps purpurea.

N1-acyl prodrugs (the market majority). ALD-52, 1P-LSD, 1B-LSD, 1cP-LSD, 1V-LSD, 1D-LSD, 1T-LSD, and their relatives carry an extra chemical group on the indole nitrogen of LSD. Halberstadt et al., 2020 showed that this addition cuts affinity for most monoamine receptors — including 5-HT2A (the serotonin 2A receptor, the switch that generates psychedelic effects) — by one to two orders of magnitude, and that in calcium-mobilisation assays these molecules act as weak partial agonists or outright antagonists (an agonist switches a receptor on, a partial agonist switches it on only weakly, and an antagonist blocks it). They are, in their own right, close to inert at the target that matters. They nonetheless produce a full LSD-like behavioural signature in animals because they are rapidly cleaved back to LSD in blood, a hydrolysis that appears to be driven by serum chemistry rather than by liver enzymes. The pharmacology of this subgroup is therefore the pharmacology of LSD, offset by a conversion delay.
N6-modified lysergamides. AL-LAD (N6-allyl-6-nor-LSD) and ETH-LAD (N6-ethyl-6-nor-LSD) replace the methyl group at the ring nitrogen. These are not prodrugs; they are intrinsically active 5-HT2A agonists with their own potency and duration. AL-LAD was characterised behaviourally by Brandt et al., 2017, which found it slightly less potent than the parent compound in mice; ETH-LAD, characterised analytically in the companion report of the same series, is the more potent of the two in reported human use.
Amide-modified lysergamides. LSZ (lysergic acid 2,4-dimethylazetidide), LSM-775 (the morpholide), and MIPLA alter the diethylamide arm. LSM-775 illustrates that this region governs more than potency: Brandt et al., 2018 found its behavioural profile is partly masked by 5-HT1A activation (the serotonin 1A receptor, a calming subtype that dampens rather than generates perceptual change), so the same receptor family can be engaged in a materially different balance.
Non-hallucinogenic congeners. 2-Br-LSD (BOL-148) and the newer (+)-JRT are deliberate redesigns. Lewis et al., 2023 — a collaboration that includes employees of BetterLife Pharma, the company developing 2-Br-LSD commercially, a financial interest that should be weighed against every claim in that paper — profiled 2-Br-LSD across more than 33 receptors. It is a partial agonist at 5-HT2A, produces no head-twitch response in mice (the standard rodent proxy for hallucinogenic activity), recruits β-arrestin weakly (β-arrestin is the second of the two internal signalling arms a serotonin receptor can switch on, the one associated with shutting the receptor down), and, critically, lacks agonist activity at 5-HT2B (the serotonin 2B receptor, the subtype linked to heart-valve fibrosis). It still drives dendrite and dendritic-spine growth in cultured cortical neurons. (+)-JRT, reported by Tuck et al., 2025 from a group that includes Delix Therapeutics staff and a founder with an equity interest in the compound class, was designed by a single structural inversion and promotes cortical spine growth without worsening gene-expression signatures associated with psychosis.

Two competing mechanistic accounts run through this literature and are not resolved. The first holds that 5-HT2A agonism is both necessary and sufficient for the therapeutic effect, so removing the hallucination necessarily removes the benefit. The second holds that the growth-promoting and hallucinogenic consequences of 5-HT2A activation can be separated by biased signalling — that a molecule can engage the receptor’s protein-signalling arm while sparing the arm that generates visions. The existence of lisuride, an ergoline that binds 5-HT2A without producing hallucinations and has been used clinically for Parkinson’s disease, is the oldest evidence for the second account; the near-total absence of human efficacy data for any non-hallucinogenic analogue is the strongest evidence for the first.

Key pharmacological properties, for the prodrug subgroup that dominates real-world use:

Half-life. The measured terminal half-life of LSD released from oral 1P-LSD was approximately 6.4 hours, against roughly 3–6 hours reported for LSD administered directly, depending on dose and study (Grumann et al., 2020). The parent analogue itself is detectable for only about 4 hours in serum after intravenous dosing and disappears from urine within roughly 3 hours.
Selectivity. Low. The released molecule is promiscuous across serotonin, dopamine, and adrenergic receptor families; the prodrugs themselves are weakly selective and largely inactive.
Tissue distribution. Fat-soluble and readily brain-penetrant; the released compound distributes widely, with plasma concentrations in the picogram-to-nanogram per millilitre range at typical doses.
Metabolism. Two sequential steps. Cleavage of the added group is a hydrolysis that proceeds in serum without requiring liver enzyme activity. The LSD then released is oxidised in the liver, principally by CYP2D6 and CYP3A4 (liver enzymes that break down a large share of prescription drugs), with contributions from CYP1A2, CYP2E1, and CYP2C9, to the major inactive metabolite 2-oxo-3-hydroxy-LSD. Wagmann et al., 2019 mapped this two-stage fate across nine analogues and found that they converge on structurally identical downstream metabolites, so a positive result cannot indicate which analogue was taken — and that in rats given expected recreational doses, standard urine screening approaches detected neither the parent analogues nor their metabolites at all.

Historical Context & Evolution

Original intent was pharmaceutical, not recreational. LSD was synthesised by Albert Hofmann at Sandoz in 1938 during a programme aimed at circulatory and obstetric stimulants derived from ergot; its psychoactivity was not discovered until 1943. The first analogues followed immediately and were made for the same reason any medicinal chemistry series is made — to map which parts of the molecule do what. ALD-52 (1-acetyl-LSD) and BOL-148 (2-bromo-LSD) both date from that Sandoz programme in the 1950s.
BOL-148 became a scientific instrument before it became a candidate drug. In the mid-1950s it was used as the non-hallucinogenic comparator that let investigators separate serotonin-blocking activity from psychedelic activity, work that fed directly into the serotonin hypothesis of hallucinogen action. The finding was not that BOL-148 did nothing; it was that a compound could retain substantial serotonergic activity while producing no visions. That observation is the intellectual ancestor of the entire modern non-hallucinogenic programme, and it was made seventy years before the companies now developing it existed.
The historical claim was challenged, and the challenge is itself a claim. When Karst et al., 2010 reported an open case series in which five chronic cluster headache patients received three doses of 2-Br-LSD at five-day intervals and experienced substantial attack reduction, Tfelt-Hansen, 2011 published a direct rebuttal questioning whether the compound is genuinely non-hallucinogenic, pointing to older reports of perceptual effects at higher doses. Neither position has been settled by controlled data. The 2023 receptor profiling supports the non-hallucinogenic classification at the doses tested; the rebuttal’s point that dose-response was never characterised in humans remains unaddressed. Readers of this literature encounter the 2010 series described in some sources as definitive and in others as discredited; neither description is supported, because the study was a five-patient open series with no control group and has never been replicated.
The research-chemical era began in 2015 and was driven by law, not by pharmacology. 1P-LSD appeared on the open market in early 2015, followed by a steady procession — AL-LAD, LSZ, 1B-LSD, 1cP-LSD, 1V-LSD, 1D-LSD, 1T-LSD, 1S-LSD, 1F-LSD. Each release followed a legislative closure. Germany’s blanket new-substances legislation prompted the design of 1V-LSD specifically to sit outside its structural definitions; when that gap closed in 2022, 1D-LSD appeared within months. The analytical literature that documents this sequence — most of it produced by Simon Brandt and colleagues across seven papers between 2016 and 2022 — reads as a chemical record of regulatory pursuit.
Health optimisation entered the picture through microdosing, not through medicine. The prodrug analogues became attractive to a health-oriented audience because they made a legally obtainable, reasonably stable, and easily divided source of the parent molecule available at a time when clinical access was impossible. The framing shifted again from roughly 2023 onward, when the non-hallucinogenic branch was reclassified from historical curiosity to pharmaceutical asset and drew venture funding.
What changed in scientific opinion, and why. The 1960s consensus that these compounds were therapeutically useless was formed largely without controlled trials and alongside political pressure. The current consensus that the parent compound has genuine psychiatric activity rests on modern randomised trials. But the correction has not been symmetric: the modern trials examine the parent compound and one salt form, not the analogues, and the newer evidence on the redesigned analogues comes overwhelmingly from commercially interested laboratories. The direction of the evidence has reversed; the quality of the evidence about the analogues themselves has improved far less than the confidence surrounding them.

Expected Benefits

High 🟩 🟩 🟩

Near-complete and predictable conversion to the parent compound

For the N1-acyl subgroup, the practical benefit is pharmacokinetic rather than therapeutic: they behave as a reliable delivery form for a molecule whose dose-response, duration, and safety profile have been characterised in modern controlled human research. In the only human study of this conversion, oral 1P-LSD produced no detectable parent analogue in serum or urine at all — only LSD — with bioavailability of the released compound close to 100%. Rodent plasma measurements after ALD-52 and 1P-LSD show the same rapid and efficient cleavage, and mouse behavioural testing across the series reproduces the parent compound’s signature. The limitation is that the human work rests on two participants under controlled self-administration, so between-person variability in the conversion is entirely uncharacterised.

Magnitude: Oral bioavailability of the released compound close to 100%; terminal half-life approximately 6.4 hours; parent analogue undetectable in serum after oral dosing.

Medium 🟩 🟩

Reduction of anxiety symptoms

Anxiety reduction is the best-evidenced clinical effect of the molecule these analogues release, established in randomised placebo-controlled trials in generalised anxiety disorder and in anxiety associated with life-threatening illness, with the proposed mechanism being 5-HT2A-driven relaxation of rigid, self-referential thought patterns combined with a period of increased cortical plasticity. The grading is Medium rather than High because no analogue has been tested for this outcome; the inference travels from the trials to the analogues via the conversion evidence above, and that bridge is strong but not the same thing as direct evidence. All the trial data come from supervised single administrations with psychological support, a context absent from essentially all real-world analogue use.

Magnitude: Roughly 7–8 points greater improvement than placebo on the 56-point Hamilton Anxiety Rating Scale in the largest controlled trial of the parent compound at a 100 µg dose.

Reduction of depressive symptoms

Depressive symptoms improve after supervised administration of the molecule these analogues release, through the same 5-HT2A-driven plasticity window proposed for the anxiety effect. The evidence basis is a Bayesian network meta-analysis (a statistical method that pools trials to rank several treatments against one another, including ones never compared head to head) of psychedelic and antidepressant monotherapy that places the parent compound among the more effective single-dose options examined, plus controlled trials in which depressive scores improved alongside the primary anxiety endpoint; a Phase 3 programme in major depressive disorder has completed its primary assessment but has not reported. The grading is Medium rather than High for the same reason as anxiety: no analogue has been tested for this outcome, so the inference travels through the conversion evidence rather than through direct data. Durability beyond a few months, and any effect outside a supervised setting, remain uncharacterised.

Magnitude: Not quantified in available studies.

Reduction of problem alcohol and substance use

Single-dose administration of the parent compound was associated with reduced alcohol consumption in a series of controlled trials conducted in the 1960s and 1970s, and the proposed mechanism is the same period of cognitive flexibility that clinical protocols pair with psychological support. The evidence basis is a meta-analysis of six randomised controlled trials in over 500 patients treated for alcohol misuse, which found a significant short-term benefit that faded within a year, supported by more recent observational work on psychedelic use and drinking reduction. The grading is Medium because the underlying trials predate modern methodological standards, used varied comparators, and again involve the parent compound rather than any analogue. Nothing in this literature speaks to the low-dose regimens for which the analogues are most often bought.

Magnitude: Roughly a doubling of the odds of improvement in alcohol misuse at the first follow-up in pooled trial data, with no measurable difference remaining by twelve months.

Mood elevation and increased vigour at low doses ⚠️ Conflicted

Low-dose regimens — commonly a tenth or less of a full dose, taken every second or third day — are the most common reason a health-oriented adult buys a prodrug analogue, and the evidence for them is genuinely split. Laboratory studies using single blinded low doses of the parent compound have detected reliable increases in vigour, and acute mood effects at the upper end of the low-dose range. Against this, the largest self-blinding placebo-controlled citizen-science study found that expectancy accounted for most of the reported benefit, and the systematic review of low-dose side effects noted that outcome measurement across this literature is heterogeneous enough to defeat pooled estimation. The honest reading is that acute, dose-dependent effects on subjective energy are real and that durable improvements in mood and wellbeing are not established.

Magnitude: Detectable increases in subjective vigour and drug-liking at single doses in the 13–26 µg range of the parent compound; no reliable effect size established for repeated dosing.

Low 🟩

Cluster headache prevention with the non-hallucinogenic congener

2-Br-LSD is the only analogue with any published human therapeutic data. Five patients with chronic cluster headache received three doses at five-day intervals in an open, non-randomised series and experienced marked reductions in attack frequency without hallucinogenic effects. The proposed mechanism is serotonergic modulation of the trigeminovascular system (the nerve and blood vessel network that carries head pain), shared with the ergot-derived and triptan drugs already used for this condition. The evidence basis is a single uncontrolled case series of five people from 2010 that has never been replicated, and a published rebuttal disputes the non-hallucinogenic characterisation. This is a real signal in a condition with few good options, not a demonstrated benefit.

Magnitude: Marked reduction in attack frequency in 5 of 5 patients in one open series; no controlled estimate exists.

Receptor profile that avoids the heart-valve liability

2-Br-LSD lacks agonist activity at 5-HT2B, the serotonin receptor subtype whose chronic stimulation caused the valve fibrosis that removed fenfluramine and pergolide from the market. Since the prodrug analogues deliver a molecule that does activate 5-HT2B, a congener without that activity is a genuinely meaningful differentiator for anyone contemplating repeated long-term dosing rather than occasional use. The evidence is in vitro receptor pharmacology from a single laboratory whose author list includes the developing company’s staff, with no echocardiographic data in humans or animals. It is a structural argument for lower risk, not an observed reduction in valve disease.

Magnitude: No measurable 5-HT2B agonist activity in receptor assays, against clear agonist activity for the parent compound.

Structural neuroplasticity without hallucinogenic effect

Both 2-Br-LSD and (+)-JRT increase dendrite branching and dendritic-spine density in cortical neurons and improve performance on rodent assays of active coping and cognition, while producing no head-twitch response. The proposed mechanism is 5-HT2A engagement biased away from the signalling arm associated with perceptual distortion. The evidence is entirely preclinical: cultured neurons and mice, with the JRT work additionally showing no worsening of psychosis-relevant gene-expression signatures. The systematic review of this branch of the field found five animal studies and one human case report in the entire published literature.

Magnitude: Not quantified in available studies.

Choice of onset and duration profile

Different acyl groups hydrolyse at different rates, so the subgroup offers a spread of onset and duration characteristics from a single underlying pharmacology — shorter-chain compounds such as ALD-52 and 1P-LSD convert quickly, while longer-chain compounds show delayed onset. The practical value is scheduling flexibility, and the first-in-human trial of a genuinely short-acting analogue, didehydro-LSD (DDH-LSD), is now underway on exactly this rationale. The evidence for the differences is rodent behavioural time-course data and in vitro hydrolysis rates, with no human head-to-head comparison published.

Magnitude: Not quantified in available studies.

Raised pain tolerance at low doses ⚠️ Conflicted

Single low doses of the molecule these analogues release raise tolerance to experimentally induced pain, with the proposed mechanism being serotonergic modulation of how pain signals are processed rather than the sedation or receptor blockade that conventional painkillers rely on. The evidence is directly conflicted: a randomised placebo-controlled crossover in 24 healthy volunteers found that 20 µg significantly lengthened cold-pressor tolerance (how long a hand can be held in ice water) and reduced rated painfulness and unpleasantness, while a later randomised placebo-controlled study giving 15 µg over four administrations found no effect on any pain measure in the full sample and only a marginal one in a subgroup without a ceiling effect. Marked pain relief at full doses was reported in terminally ill patients in the 1960s and 1970s, but that work predates modern methodological standards. No analogue has been tested for this outcome, and no controlled study has examined pain in a clinical pain population at any dose.

Magnitude: Significantly longer cold-pressor tolerance after a single 20 µg dose of the parent compound in healthy volunteers, against no measurable effect at 15 µg in a repeated-dose study.

Speculative 🟨

Sustained regimens without tolerance build-up

Repeated dosing of the parent compound produces rapid tolerance, which caps how often it can be used and is a structural obstacle to any maintenance regimen. 2-Br-LSD did not induce tolerance after repeated administration in mice, raising the possibility of a genuinely sustainable schedule. This rests on a single rodent experiment in a commercially interested paper, with no human data of any kind, and no demonstration that a non-tolerising compound would retain benefit across repeated doses.

Effects on cognitive and functional ageing

The longevity-adjacent case for this class is that periodic promotion of cortical dendritic growth might slow or partly offset the loss of synaptic density that accompanies ageing, and that a compound producing this effect without hallucinations would be usable at ages where a full psychedelic session is impractical. There are no controlled studies of any analogue on any ageing outcome, no lifespan or healthspan data, and no human imaging of structural change after analogue exposure. The basis is mechanistic extrapolation from rodent spine-density work plus observational reports associating psychedelic use in older adults with better cognitive scores, which cannot separate the drug from the population that uses it.

Immune and inflammatory modulation at low doses

Cell and animal work on the parent compound has reported suppression of inflammatory signalling molecules including tumour necrosis factor alpha and interleukin 6 at concentrations achievable with low doses, which would be relevant to any longevity framework built around chronic low-grade inflammation. No human study has measured inflammatory markers after administration of any LSD analogue, and no controlled study has measured them after low-dose administration of the parent compound. The basis is mechanistic and in vitro only.

Cognitive performance and creativity at low doses

Sharper focus, faster problem-solving, and greater creative fluency are, alongside mood, the most commonly stated reasons a health-oriented adult takes a low-dose regimen, and the proposed mechanism is the same 5-HT2A-driven loosening of rigid processing invoked for the mood effect. Controlled evidence does not support the claim: a 2026 meta-analysis pooling 14 microdosing studies in 1,614 participants across 59 effect sizes found no detectable improvement in any cognitive domain and a significant reduction in cognitive control, with neither the substance, the dose, nor the duration of use acting as a moderator (a factor that changes the size of the result). The systematic review of low-dose side effects separately lists cognitive impairment among the commonest reported effects, so the measured direction of travel is opposite to the claimed one. The basis for the benefit is therefore uncontrolled self-report and the expectancy effect documented in the self-blinding literature rather than measured performance, which is why it is placed here rather than among the graded items.

Benefit-Modifying Factors

CYP2D6 metabolism status: CYP2D6 is the liver enzyme that performs much of the breakdown of the released compound. People carrying two non-functional copies — roughly 5–10% of those of European ancestry — clear it more slowly, producing higher blood levels and effects that run substantially longer at the same dose. Ultrarapid metabolisers show the reverse. This is the single largest identified source of between-person variability in response.
HTR2A receptor variants: Common polymorphisms in HTR2A (the gene encoding the 5-HT2A receptor that mediates the primary effect), including the rs6313 variant, have been associated with differences in receptor density and in subjective response intensity to serotonergic psychedelics. The evidence is inconsistent across studies and the effect size is small relative to CYP2D6 status.
Baseline serotonergic medication exposure: Ongoing treatment with a selective serotonin reuptake inhibitor (an SSRI, the most common antidepressant class) or a serotonin-noradrenaline reuptake inhibitor (an SNRI, a closely related antidepressant class) markedly blunts the subjective and probably the therapeutic response, through downregulation of the target receptor (the cell reduces the number of available receptors, so the same dose produces less effect). This is a baseline state that can nullify the intervention entirely rather than merely attenuate it, and it is the most common reason a motivated user experiences nothing.
Baseline anxiety and depressive symptom severity: In the controlled trials of the parent compound, absolute improvement scales with starting severity — people entering with higher anxiety scores improve more in absolute terms. For someone already functioning well and using the compound for optimisation rather than treatment, the expected mood benefit is correspondingly smaller.
Baseline blood pressure: People starting from higher resting blood pressure experience the same absolute acute rise from a higher and less comfortable baseline, which constrains dose more than it constrains benefit, and shifts the risk-benefit balance unfavourably before any therapeutic effect is realised.
Sex differences: Controlled pharmacokinetic work with the parent compound has found modestly higher plasma concentrations in women at equal absolute doses, largely explained by body weight, with no consistent difference in therapeutic response once dose is corrected. No analogue has been studied for sex differences at all.
Pre-existing psychiatric conditions: Existing anxiety or depressive disorders predict larger measurable improvement; a personal or first-degree family history of bipolar disorder or a psychotic disorder predicts harm rather than benefit and is an exclusion in every clinical protocol.
Age: Reduced hepatic clearance and increased cardiovascular sensitivity in later decades both argue for lower doses; against this, the observational signal associating psychedelic use with better cognitive scores in older adults is strongest in exactly this group. For adults at the older end of the target range, the plausible benefit may be larger while the tolerable dose is smaller.
Set, setting, and expectancy: The self-blinding low-dose evidence indicates expectancy accounts for a large share of reported benefit at low doses, and the full-dose trials treat preparation and supervision as inseparable from the molecule. Context is not a minor modifier here; at low doses it may be the dominant one.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Acute anxiety, panic, and confusion

The dominant acute harm of this class is psychological: intense anxiety, fear of losing control, paranoia, and disorientation during the active period, which for the prodrug analogues runs 8–12 hours. The mechanism is the same 5-HT2A activation that produces the intended effect, so the adverse and therapeutic effects are not separable at full doses. The evidence basis is direct: the pooled analysis of 214 psychedelic studies identifies anxiety among the most frequent adverse events, and the low-dose systematic review finds anxiety among the three commonest side effects even at a tenth of a full dose. Severity is usually self-limiting and resolves with the drug, but distress during an unsupervised 12-hour episode can produce lasting secondary consequences.

Magnitude: Among the most frequently reported adverse events across pooled psychedelic trials; present as a common side effect even in low-dose regimens.

Acute rise in blood pressure and heart rate

Blood pressure and heart rate increase reliably and dose-dependently, driven by direct vascular and central adrenergic effects of the ergoline structure. This is the most consistently measured physiological effect in the low-dose literature and is present at doses too small to produce noticeable subjective effects. For a health-oriented adult with normal cardiovascular status the increase is well tolerated; for anyone with untreated hypertension, coronary disease, or an arrhythmia it converts a nuisance into a hazard, and the effect persists for the full duration of action.

Magnitude: Increases of roughly 10–20 mmHg systolic and 5–15 beats per minute at full doses; smaller but measurable increases at low doses.

Nausea, headache, dizziness, and fatigue

The routine physical toll of a session is nausea in the first hour, headache during and after the active period, dizziness, and fatigue once effects subside. The mechanism is a combination of direct serotonergic action on the gut and vasculature and the length of the experience itself. The evidence basis is the strongest available for any effect in this class: the pooled analysis of 214 psychedelic studies produced comparable prevalence estimates for headache, nausea, fatigue, and dizziness across the parent compound and psilocybin, and the systematic review of a named analogue reports nausea among the typical effect profile. Severity is mild and self-limiting in almost every case, but these are the effects a first-time user is most likely to encounter and the ones most often understated in vendor material.

Magnitude: Among the most frequently reported adverse events in pooled psychedelic trials, alongside anxiety; typically resolving within the dosing day.

Impaired judgement, coordination, and accident risk

Judgement, attention, and motor coordination are degraded for the whole active period, and altered risk perception makes ordinary situations — traffic, water, heights, cooking, a confrontation — hazardous in a way the person does not register at the time. The mechanism is the same 5-HT2A activation that produces the intended effect, so the impairment cannot be separated from the experience at full doses and is only partly avoided at low ones. The evidence basis is direct measurement of psychomotor and cognitive impairment in controlled human administration of the released molecule, alongside the emergency-presentation literature in which injury and dangerous behaviour, rather than direct toxicity, account for most acute harm from this class. Severity ranges from trivial to fatal and is determined almost entirely by setting and supervision, which is why every clinical protocol confines the session to a controlled room with attendants present, and why unsupervised analogue use carries an exposure the trial literature cannot measure.

Magnitude: Impairment spans the full 8–12 hour active period and longer for the delayed-onset analogues; the registered analogue trial requires participants to abstain from operating heavy machinery for 48 hours after dosing.

Dose uncertainty from unregulated manufacture

This risk belongs to the analogues specifically rather than to the parent compound. Products are made and distributed without any quality oversight, and the forensic literature repeatedly finds that the label is wrong: blotter sold as “1D-LSD” was found to contain 1-(thiophene-2-carbonyl)-LSD instead (Okada et al., 2024), and sheet products have been found to carry mixtures of 1cP-AL-LAD, 1cP-MIPLA, 1V-LSD, and LSZ (Tanaka et al., 2023). Because these compounds differ in molecular weight, potency, and time course, a substitution converts a planned low dose into an unplanned full experience. The N1-acyl bond is also chemically labile: Zhang et al., 2023 showed that both ALD-52 and 1P-LSD hydrolyse back to LSD during laboratory analysis — in alcoholic extraction solvents and at the heated injector of a gas chromatograph — with ALD-52 the more readily hydrolysed of the two, and no shelf-life data exist for blotter held in a domestic drawer.

Magnitude: Documented instances of complete compound substitution and multi-analogue mixtures in commercially sold blotter; hydrolysis of ALD-52 and 1P-LSD back to LSD demonstrated under laboratory analytical conditions, with ALD-52 the less stable of the pair.

Medium 🟥 🟥

Precipitation of mania, hypomania, or psychosis

In people with bipolar disorder or a predisposition to psychosis, serotonergic psychedelics can trigger a manic switch or a psychotic episode that outlasts the drug by days to weeks. The mechanism is thought to involve 5-HT2A-driven cortical excitability in an already unstable system. The 2026 systematic review and meta-analysis quantifies this risk specifically, and the adverse-event synthesis found serious events — including psychosis and worsening depression — in roughly 4% of participants with pre-existing neuropsychiatric conditions against none in healthy participants. Severity can be high and recovery is not always rapid, which is why family history is a hard exclusion rather than a caution. In a screened, psychiatrically healthy population this risk is small.

Magnitude: Serious adverse events in approximately 4% of participants with pre-existing neuropsychiatric disorders in pooled trial data, against 0% in healthy participants.

Worsening depression and emergent suicidality

A minority of people deteriorate rather than improve after exposure, and suicidal behaviour sits alongside worsening depression and psychosis in the list of serious adverse events recorded in the pooled analysis of modern psychedelic trials. The proposed mechanism is the same heightened emotional access that produces the therapeutic effect, which without preparation and follow-up can surface distressing material that the person is then left to absorb alone. The evidence basis is that pooled synthesis, in which serious events of this kind occurred in roughly 4% of participants with pre-existing neuropsychiatric conditions and in none of the healthy participants, with no deaths by suicide reported in any contemporary research setting. Severity is potentially high, and the at-risk group overlaps precisely with the people most motivated to try this class for low mood, which is why supervised protocols screen for active suicidal ideation as an exclusion in its own right and treat post-session contact as part of the intervention rather than an optional extra.

Magnitude: Worsening depression and suicidal behaviour among the serious adverse events reported in approximately 4% of participants with pre-existing neuropsychiatric disorders in pooled trial data, against 0% in healthy participants; no deaths by suicide across 214 pooled modern studies.

Rapid tolerance with repeated dosing

Sensitivity falls sharply with consecutive daily doses of the parent compound and takes roughly two weeks to fully restore, through downregulation of the target receptor. This is a well-established property of the released molecule and therefore of every prodrug analogue. The practical consequence is that people escalate dose to chase a diminishing effect, which raises cardiovascular and psychological risk without restoring benefit, and it structurally prevents any daily maintenance regimen. It is a mechanistic certainty rather than a possibility, graded Medium only because its clinical consequences have not been formally quantified in the analogue class.

Magnitude: Near-complete loss of subjective effect after three to four consecutive daily full doses, with recovery over approximately 10–14 days.

Next-day impairment and sleep disruption

Effects extend 8–12 hours from a full dose and considerably longer for the delayed-onset analogues, so evening dosing routinely displaces a night of sleep, and residual fatigue, reduced concentration, and mild dysphoria (a flat, low, uneasy mood) the following day are commonly reported. The mechanism is a combination of direct sleep architecture disruption and simple duration. The low-dose systematic review identifies cognitive impairment among the commonest side effects. For an audience that treats sleep as foundational, repeated regimens impose a sleep cost that can plausibly exceed the mood benefit.

Magnitude: Active duration of 8–12 hours for the common prodrug analogues, with delayed-onset compounds extending beyond this.

Low 🟥

Hallucinogen persisting perception disorder ⚠️ Conflicted

Hallucinogen persisting perception disorder is the persistence of visual disturbances — trails, halos, visual snow — for months or years after exposure. The evidence is genuinely contradictory: it is a recognised diagnosis with a substantial case-report literature and a documented association with repeated high-dose use, yet the systematic review of 214 modern psychedelic studies found no reported cases at all in contemporary trial settings. The discrepancy may reflect dose, screening, frequency, or under-ascertainment in trials that were never designed to detect it. No case has been formally attributed to an LSD analogue, though the analogues deliver the same molecule.

Magnitude: No cases reported across 214 pooled modern studies; case-series literature exists outside trial settings, with no reliable population estimate.

Cardiac valve fibrosis with chronic exposure

The released molecule is an agonist at 5-HT2B, the receptor whose sustained stimulation caused valvular heart disease with fenfluramine, pergolide, and high-dose cabergoline. The concern is specific to frequent long-term dosing rather than occasional use, and it is the most longevity-relevant risk in this review because valve damage is cumulative and largely irreversible. The evidence is mechanistic and by class analogy only: no echocardiographic study of frequent psychedelic users has been published, so neither the presence nor the absence of the effect at these exposures has been demonstrated. Intermittent full doses deliver far less cumulative receptor exposure than the daily therapeutic doses of the withdrawn drugs.

Magnitude: Not quantified in available studies.

Predicted organ toxicity signals from computational modelling

The only systematic toxicological assessment of this specific class is computational. Jurowski et al., 2026 modelled five common prodrug analogues across several platforms and produced predicted rat oral lethal doses of 49–85 mg/kg, elevated pulmonary risk flags for 1V-LSD and 1cP-LSD, hematotoxicity flags (predicted harm to blood cells) for 1P-LSD and 1B-LSD, genotoxicity alerts (predicted damage to DNA) for ALD-52 and 1cP-LSD, and the strongest predicted hERG potassium-channel inhibition (hERG is the channel governing normal heart rhythm) for 1V-LSD. These are software predictions, not measurements; one platform in the same study classified all five as non-mutagenic (not predicted to cause permanent changes to DNA). They are grounds for monitoring, not for a claim of demonstrated toxicity.

Magnitude: Predicted hERG half-maximal inhibition of 1.4 µM for 1V-LSD; predicted pulmonary toxicity probability of 92% for 1V-LSD and 81% for 1cP-LSD; predicted rat oral lethal dose 49–85 mg/kg.

Speculative 🟨

Impurity and by-product exposure from grey-market synthesis

Analogue synthesis is performed by unregulated laboratories, and the analytical literature that characterises these products routinely reports detectable impurities alongside the intended compound, including isomerisation and light-degradation products. Since the material is consumed in microgram quantities, an impurity present at a few percent is present in nanogram amounts, which limits the plausible toxicological consequence for most contaminants. There are no toxicity studies of any identified impurity in this class and no systematic purity surveillance, so the actual exposure profile is unknown.

Long-term receptor regulation from sustained low-dose use

Sustained low-dose regimens continuously occupy a receptor system that normally sees only phasic signalling (brief bursts of activity rather than continuous stimulation), and the theoretical concern is persistent downregulation with consequences for mood regulation, or a withdrawal-like rebound on cessation. No study has followed low-dose users long enough to detect this, no receptor imaging has been performed after chronic low-dose exposure, and no rebound syndrome has been documented. The basis is mechanistic reasoning by analogy to other chronic serotonergic exposures.

Risk-Modifying Factors

CYP2D6 poor metaboliser status: The same reduced clearance that raises exposure and prolongs effects also amplifies every dose-dependent adverse effect — the cardiovascular rise, the duration of any acute psychological difficulty, and next-day impairment. Poor metabolisers effectively receive a larger and longer dose than intended.
Baseline blood pressure and cardiovascular status: Resting blood pressure is the single most useful pre-dose measurement. Untreated hypertension, known coronary disease, an arrhythmia, or existing valve abnormality all convert the predictable acute rise in blood pressure from tolerable to consequential, and existing valve disease additionally compounds the theoretical 5-HT2B concern.
Personal or family history of bipolar disorder or psychosis: A first-degree relative with a psychotic or bipolar disorder is the strongest single predictor of serious harm in this class, and is an exclusion criterion in every registered trial of the parent compound rather than a factor to be weighed.
Concurrent serotonergic or lithium therapy: Lithium co-administration with serotonergic psychedelics has been associated with seizures in case reports and is treated as an absolute contraindication. SSRIs blunt effect rather than raise risk, but the blunting frequently drives dose escalation, which raises risk indirectly.
Sex differences in risk: Women reach modestly higher plasma concentrations at equal absolute doses, largely explained by body weight, so weight-uncorrected dosing gives women a slightly larger effective exposure and correspondingly greater dose-dependent side effects. No sex-specific serious adverse event pattern has been established for this class.
Age: Reduced hepatic clearance, higher baseline blood pressure, greater prevalence of undiagnosed coronary and valve disease, and a larger number of concurrent prescription medications all raise risk in later decades. For adults at the older end of the target range, cardiovascular screening before a first full dose is more consequential than at any other point in the range.
Pre-existing hepatic or renal impairment: Reduced liver function slows clearance of the released compound and extends its exposure; reduced kidney function delays elimination of its metabolites. Neither has been studied in this class, so the practical implication is dose conservatism rather than a defined adjustment.
Frequency and cumulative exposure: Almost every serious risk in this class — tolerance, the theoretical valve concern, persisting perceptual disturbance, receptor downregulation — scales with frequency rather than with single-dose size. Cumulative exposure is the risk variable that individual dose decisions most often ignore.

Key Interactions & Contraindications

Lithium: Absolute contraindication. Co-administration with serotonergic psychedelics has produced seizures and status epilepticus (a seizure that does not stop on its own) in case reports. No mitigation exists short of avoidance; discontinuation of lithium is a psychiatric decision with its own substantial risks, not a workaround.
Selective serotonin reuptake inhibitors and serotonin-noradrenaline reuptake inhibitors (fluoxetine, sertraline, escitalopram, paroxetine, venlafaxine, duloxetine): Caution and expectation management rather than danger. Chronic use markedly blunts the response through receptor downregulation, and the clinical consequence is usually a failed and repeated attempt at escalating dose. Paroxetine, fluoxetine, and bupropion additionally inhibit CYP2D6, which raises exposure to the released compound and pulls in the opposite direction, making the net effect unpredictable. No dose adjustment is reliable; separation in time is ineffective because the blunting is adaptive rather than acute.
Monoamine oxidase inhibitors (an older antidepressant class that blocks the enzyme clearing serotonin and related signalling molecules; phenelzine, tranylcypromine, moclobemide, selegiline): Caution. Reported effects range from marked blunting to potentiation, and the direction is not predictable from the drug alone. Clinical protocols require washout before administration of the parent compound.
Tricyclic antidepressants and non-lithium mood stabilisers (imipramine, amitriptyline, nortriptyline; valproate, lamotrigine, carbamazepine): Caution. Tricyclics potentiate the subjective and cardiovascular effects, so the intended dose behaves as a larger one, and dose reduction of the analogue is the only available mitigation. The anticonvulsant mood stabilisers carry no reported seizure interaction of the kind that makes lithium an absolute contraindication, but none has been studied in combination with this class, so the practical implication is dose conservatism rather than a defined adjustment.
Antipsychotics (risperidone, olanzapine, haloperidol, quetiapine): Caution as a chronic medication, useful as an acute measure. These block the target receptor and abolish the effect; the same property makes 5-HT2A-blocking agents the standard means of terminating an overwhelming episode in clinical settings.
Other 5-HT2B agonists and ergot derivatives (cabergoline, bromocriptine, pergolide, methysergide, ergotamine): Caution, with the clinical consequence being additive cumulative exposure at the receptor implicated in valve fibrosis. Concurrent long-term use of two 5-HT2B agonists is the specific combination worth avoiding; echocardiographic monitoring is the mitigation if it cannot be.
Triptans and vasoconstrictive migraine drugs (sumatriptan, rizatriptan, ergotamine): Caution, with additive vasoconstriction and additive serotonergic load as the clinical consequence. Separation by at least 24 hours is the practical mitigation, which is relevant because cluster headache is one of the few indications in which this class is deliberately used.
Stimulants, prescription and over-the-counter (amphetamine, methylphenidate, modafinil, pseudoephedrine, phenylephrine, high-dose caffeine): Caution, with additive blood pressure and heart rate elevation as the clinical consequence. Pseudoephedrine and phenylephrine in over-the-counter decongestants are the most commonly overlooked members of this group. Omitting them on dosing days is straightforward mitigation.
Over-the-counter dextromethorphan and diphenhydramine: Caution. Dextromethorphan adds serotonergic and dissociative activity and inhibits CYP2D6; diphenhydramine adds anticholinergic confusion (blockade of acetylcholine, the signalling molecule the brain uses for memory and attention) to an already altered state. Both appear in multi-ingredient cold preparations.
Serotonergic supplements (5-HTP, short for 5-hydroxytryptophan, a direct building block the body converts into serotonin; L-Tryptophan; St. John’s wort; SAMe, short for S-adenosylmethionine, a methyl-donor supplement taken for mood; high-dose L-Tyrosine): Caution, with additive serotonergic load and, for St. John’s wort, chronic receptor downregulation that blunts response exactly as an SSRI does. Separation by at least a week before dosing is the practical mitigation for the reuptake-affecting members.
Supplements with additive blood-pressure or vasoconstrictive effects (synephrine, yohimbine, high-dose caffeine, liquorice root, ephedra-containing preparations): Caution, with additive blood-pressure elevation as the clinical consequence. These matter more here than they would with most interventions because the analogue itself reliably raises blood pressure for the entire duration of action. Omitting them for 24 hours before and during dosing is sufficient.
Supplements that plausibly blunt or modify the response (magnesium at high doses, cannabidiol, ashwagandha): Monitor only. Cannabidiol and cannabis are the practically important members; cannabis co-use consistently intensifies anxiety and perceptual disturbance rather than smoothing them.
Other interventions: Concurrent psychotherapy carries no interaction severity — it is complementary rather than interacting, with the clinical consequence being an enhanced rather than altered response, and it is treated as part of the intervention in every clinical protocol. Concurrent transcranial magnetic stimulation or ketamine therapy warrants caution, with the clinical consequence being unpredictable additive plasticity and cardiovascular effects because the combination has never been studied; separation by at least one week is the practical mitigation. Alcohol warrants caution, with the clinical consequence being additive cardiovascular load and compounded impairment of judgement across an already long window; abstaining from the dosing day through the following morning is the mitigation.
Populations who should avoid this intervention entirely: personal history of any psychotic disorder or bipolar I disorder, or a first-degree relative with either; active suicidal ideation or a suicide attempt within the past 12 months; current lithium therapy; uncontrolled hypertension above 140/90 mmHg; myocardial infarction within 6 months, unstable angina, or NYHA Class III–IV heart failure (New York Heart Association Class III–IV, meaning symptoms on light activity or at rest); known moderate or severe valvular regurgitation (a heart valve that leaks blood backwards); a seizure disorder; Child-Pugh Class B or C liver impairment; pregnancy or breastfeeding; existing hallucinogen persisting perception disorder; and any situation requiring driving or safety-critical work within 24 hours of dosing.

Risk Mitigation Strategies

Analytical verification of every batch before first use: Mitigates the dose-uncertainty risk that documented compound substitution and multi-analogue mixtures make the most probable serious harm in this class. Colourimetric reagent testing (Ehrlich reagent) confirms only the presence of an indole and cannot distinguish 1P-LSD from 1V-LSD; distinguishing them requires laboratory analysis through an anonymous drug-checking service that reports quantitative composition.
Low starting dose with slow escalation across separate sessions: Mitigates the acute anxiety, cardiovascular, and next-day impairment risks by establishing individual sensitivity before committing to a full dose. A practical approach is to begin at roughly a quarter of the intended dose, wait a minimum of 14 days for tolerance to fully reset, then increase by no more than 50% per session.
Cardiovascular screening before a first full dose: Mitigates the acute blood-pressure risk and the risk of an unrecognised valve or coronary problem. Resting blood pressure measured on three separate days, a resting electrocardiogram, and — for anyone contemplating repeated dosing over months — a baseline echocardiogram documenting valve status.
Hard exclusion on psychiatric family history rather than case-by-case judgement: Mitigates the mania and psychosis risk, which is the highest-severity outcome documented in pooled trial data. A first-degree relative with bipolar disorder or a psychotic disorder is treated as disqualifying in every clinical protocol, and the same rule applied personally removes most of the serious-harm probability. The same screen covers active suicidal ideation, which mitigates the worsening-depression and suicidality risk and is an independent exclusion in every registered trial rather than a factor to be weighed.
Fixed minimum interval of 14 days between full doses: Mitigates tolerance-driven dose escalation and limits cumulative receptor exposure relevant to the theoretical valve concern. This interval is long enough for receptor sensitivity to restore, so it prevents the escalation spiral rather than merely slowing it.
A defined cap on total annual exposure: Mitigates the cumulative-exposure risks — valve fibrosis, persisting perceptual disturbance, receptor downregulation — that scale with frequency rather than dose. A practical ceiling used in supervised settings is 4–6 full sessions per year, with low-dose regimens capped at 8–12 weeks before a break of at least 4 weeks.
Morning dosing with the following day cleared: Mitigates sleep disruption and next-day impairment given the 8–12 hour duration. Dosing before 10:00 places the end of the active period well before habitual sleep onset; delayed-onset analogues such as 1V-LSD require an earlier start.
Presence of a sober, informed companion for full doses: Mitigates the acute anxiety and confusion risk and the accident risk that impaired judgement creates, the first being the most common adverse event and the one most amenable to non-pharmacological management. This is the single element that every clinical protocol treats as non-negotiable and that unsupervised use most often omits.
A pre-agreed pharmacological exit: Mitigates the small proportion of acute psychological episodes that do not resolve with reassurance. Access to a 5-HT2A-blocking agent, most commonly risperidone or olanzapine, terminates the effect; this requires a clinician relationship arranged in advance rather than improvised.
Medication and supplement audit two weeks before dosing: Mitigates the interaction risks above, most importantly the absolute lithium contraindication and the additive blood-pressure elevation from over-the-counter decongestants. A two-week window allows both discontinuation of short-acting agents and a decision about whether any long-half-life agent makes dosing inadvisable at all.
Cool, dark, dry storage of blotter with a defined discard date: Mitigates the chemical lability of the N1-acyl bond, most pronounced for ALD-52, which under warm, humid, or lit conditions is expected to produce silently declining potency and to encourage compensatory dose increases; the lability itself is demonstrated only under laboratory analytical conditions, and ambient degradation rates have never been measured. Sealed, foil-wrapped, frozen storage with a discard date at 12 months is the practical form.

Therapeutic Protocol

No LSD analogue has an approved indication or an established clinical protocol anywhere. What follows describes the three protocol families actually in use, with their originators, and is descriptive rather than prescriptive.

Supervised full-dose model: The dominant clinical template comes from the Liechti group at University Hospital Basel and, before them, from Peter Gasser’s Swiss compassionate-use work in anxiety associated with life-threatening illness. Structure is a preparatory session, a supervised dosing day of 8–12 hours with two attendants present and minimal external stimulus, and one or more integration sessions afterwards. Doses in the underlying trials are 100–200 µg of the parent compound. Applied to a prodrug analogue, the mass equivalent is higher because the added group carries weight without activity: 100 µg of the parent compound corresponds to approximately 113 µg of ALD-52, 117 µg of 1P-LSD, 121 µg of 1cP-LSD, and 126 µg of 1V-LSD.
Low-dose repeated model: Popularised by James Fadiman, whose schedule is one dose followed by two days off, repeated for several weeks. A widely used variant attributed to Paul Stamets runs four days on and three off. Doses are typically a tenth or less of a full dose. The competing approach — a single low dose taken irregularly for a specific occasion rather than on a schedule — has no named originator and has not been compared with the scheduled regimens in any trial. Neither should be framed as standard, because the strongest controlled evidence indicates that expectancy accounts for much of the reported benefit from either.
Non-hallucinogenic congener model: The only published human protocol is that of Karst and colleagues at Hannover Medical School, who gave 2-Br-LSD at 20 µg/kg on three occasions at five-day intervals for cluster headache. This model differs fundamentally from the other two in that it requires no supervision, no set and setting management, and no integration, because it produces no altered state. It is also supported by five patients.
Best time of day: Morning, and for full doses before 10:00. The 8–12 hour active period must end well before habitual sleep onset, and the delayed-onset analogues — 1V-LSD, 1H-LSD, 1DD-LSD — require starting earlier still. Low doses are taken on waking; taking them after midday reliably interferes with sleep.
Half-life and its protocol implications: The released compound has a terminal half-life of roughly 3–6 hours, measured at approximately 6.4 hours when delivered from oral 1P-LSD. Because five half-lives are needed for near-complete elimination, meaningful blood levels persist into the following morning after an afternoon dose. This is the pharmacological reason morning dosing is not merely a convention.
Single versus split dosing: Single dosing throughout. Splitting a full dose extends an already long duration without increasing peak effect and complicates the decision point at which an emerging difficult experience could be managed. Redosing during a session is specifically counterproductive, because acute tolerance develops within the session itself. Low doses are likewise taken as a single morning dose.
Genetic factors influencing dose choice: CYP2D6 genotype is the most actionable. In poor metabolisers a given dose behaves as a larger and substantially longer one, so the protocols in use start proportionally lower; ultrarapid metabolisers experience the reverse. HTR2A variants including rs6313 have been associated with differences in response intensity but not consistently enough to guide dosing. COMT genotype (COMT is the enzyme that clears dopamine from the prefrontal cortex and shapes the response to stress) has been proposed as a modifier of experience quality without supporting data in this class.
Sex-based differences in dosing: Equal absolute doses produce modestly higher plasma concentrations in women, an effect largely explained by body weight rather than by sex-specific metabolism. Weight-adjusted dosing removes most of the difference; no evidence supports a sex-specific efficacy adjustment beyond that.
Age-related considerations: Reduced hepatic clearance argues for starting at 50–75% of a standard dose from roughly the sixth decade onward, and higher cardiovascular risk argues for screening before rather than after. For adults at the older end of the target range the constraint is cardiovascular rather than psychological, and it tightens the tolerable dose more than it changes the schedule.
Baseline biomarkers influencing response: Resting blood pressure determines the tolerable dose ceiling. Current SSRI or SNRI use is the strongest single predictor of a non-response and warrants either postponement or an explicit acceptance that the session may produce nothing. Baseline anxiety and depression scores predict the size of measurable improvement.
Pre-existing conditions influencing response: Existing anxiety or depressive disorders predict larger measurable benefit; a psychotic or bipolar history predicts harm and excludes; migraine and cluster headache are the conditions in which the non-hallucinogenic model rather than the full-dose model applies; and hepatic impairment prolongs everything.

Discontinuation & Cycling

Intended duration of use: Neither model in this class is designed to be lifelong. The full-dose model is intermittent by pharmacological necessity, since tolerance makes frequent dosing pointless; a small number of sessions per year is the ceiling that the pharmacology itself imposes. The low-dose model is the one at risk of drifting into indefinite daily-adjacent use, and nothing in the evidence base supports open-ended continuation.
Withdrawal effects: None documented. These compounds do not produce physical dependence, and no withdrawal syndrome has been described for the parent compound or any analogue. Reported low mood after stopping a low-dose regimen is more plausibly a return to baseline plus loss of an expectancy effect than a withdrawal state, though no controlled cessation study has been performed to distinguish the two.
Tapering: Not applicable and not required. Because there is no dependence and no withdrawal syndrome, abrupt cessation from any regimen in this class carries no known physiological consequence, and dose tapering serves no purpose.
Cycling for efficacy: Cycling is mandatory rather than optional for full doses, because tolerance develops within days and takes approximately two weeks to reset. The 14-day minimum interval is a pharmacological requirement, not a precaution. For low-dose regimens, the schedules in use build cycling in at the level of individual days — one on, two off, or four on, three off — precisely to stay ahead of tolerance, and a longer cycle of 8–12 weeks of use followed by at least 4 weeks off is common practice to limit cumulative exposure.
Signals to stop rather than cycle: Persistent visual disturbance between doses, a rising resting blood pressure, sleep that does not normalise on off-days, or the appearance of elevated mood that outlasts the drug are each grounds for discontinuation rather than schedule adjustment, since the last of these is the earliest sign of the mood-switch risk.

Sourcing and Quality

There is no legitimate supply chain: No LSD analogue is manufactured under pharmaceutical quality standards for human use, and none is available from a compounding pharmacy on prescription. The market consists of online vendors selling material designated for laboratory research, with no regulatory oversight of identity, purity, or content. This is the defining sourcing fact of the class and it cannot be mitigated to the level a supplement buyer would consider normal.
Identity verification matters more than purity: The documented failure mode is substitution, not contamination — blotter labelled as one analogue containing a different one, and sheets carrying mixtures. Because the analogues differ in potency and time course, an identity error is a dose error. Anonymous drug-checking services that perform chromatographic analysis and report quantitative composition — DrugsData, Energy Control International, and WEDINOS among them — are the only means of establishing what a product actually contains; reagent colour tests confirm only that an indole is present and cannot distinguish members of this class from each other.
Vendor certificates of analysis require independent confirmation: Some vendors supply analytical certificates. These are unverifiable, frequently generic to the compound rather than to the batch, and cannot substitute for testing the material actually received.
Formulation determines dose accuracy: Blotter is the dominant format and is the least accurate, because content per square depends on the evenness of application. Volumetric solution in ethanol or propylene glycol permits far more accurate low doses, which is why the low-dose regimens in this class are more reliably executed from solution than from cut blotter squares. Solution requires refrigeration and light exclusion.
Stability is a genuine quality variable: ALD-52 and 1P-LSD have both been shown to hydrolyse back to LSD under laboratory analytical conditions, ALD-52 more readily than 1P-LSD, and no shelf-life study of blotter held in domestic conditions exists, so shifting content over time can be neither ruled out nor seen. The practical implications are foil-wrapped, sealed, frozen storage away from light and humidity, a written acquisition date, and a discard decision rather than a compensatory dose increase when an older batch feels weaker.
Hemitartrate versus freebase content: Material is usually supplied as the hemitartrate salt, and quoted doses may refer to salt or to freebase weight without stating which. The hemitartrate salt is roughly four-fifths parent compound by weight, so the difference is on the order of 20%, and it compounds with the molecular-weight difference between the analogue and the compound it releases. Where a vendor does not state the basis, the quoted figure carries an unresolved uncertainty of that size.
Third-party testing is available but is not the supplement model: Independent laboratories that accept anonymous samples exist in several jurisdictions and publish results publicly — DrugsData, operated by the Erowid Center in the United States, Energy Control International in Spain, which accepts postal samples from abroad, and WEDINOS in Wales, which tests free of charge within the United Kingdom. This is the closest available equivalent to third-party supplement testing, and it differs in one crucial respect: it tests the sample sent, not the product line, so a result applies to one batch only.

Practical Considerations

Time to effect: For full doses, effects begin 30–90 minutes after ingestion for the shorter-chain prodrugs and later for the delayed-onset compounds, peak at 2–4 hours, and resolve over 8–12 hours; any therapeutic mood benefit in the trial literature appears in the days following a session rather than during it. For low-dose regimens, acute effects on energy appear within 1–2 hours, and proponents describe cumulative effects over 2–4 weeks that controlled evidence has not confirmed.
Common pitfalls: Dosing by blotter square rather than by verified content; assuming mass equivalence with the parent compound and thereby underdosing by 10–20%; redosing within a session against acute tolerance; escalating dose to overcome SSRI-induced blunting; afternoon or evening dosing that costs a night of sleep; treating a vendor certificate as verification; and continuing a low-dose regimen indefinitely without a defined endpoint.
Regulatory status: Highly variable and unstable. The parent compound is a Schedule I controlled substance in the United States and equivalently controlled in most jurisdictions. The analogues occupy a shifting position: several are explicitly scheduled in some countries, several fall under generic analogue provisions such as the US Federal Analogue Act or the UK Psychoactive Substances Act, and newly released compounds are typically legal in some jurisdictions at the moment of release and prohibited within one to two years. Possession of a compound that is unscheduled in one country may constitute a serious offence in the next, and legality at the time of purchase does not survive a subsequent listing. There is no off-label medical route, because there is no on-label use.
Cost and accessibility: Cost is not a limiting factor — material sufficient for a year of low-dose use typically costs less than a month of most prescription medications. Accessibility is limited by legal exposure and by the absence of any supervised setting rather than by price. The genuinely expensive component is the one the clinical protocols consider essential: preparation, supervision, and integration by trained personnel, which where legally available costs on the order of thousands per session and is the reason unsupervised use predominates. No insurer or national health system reimburses either route, so no institutional payer has a financial stake in which one is favoured; the structural bias sits instead with the sponsors, whose returns depend on patentable single molecules and who therefore have no reason to fund research on the unpatentable grey-market analogues that most people actually use.

Interaction with Foundational Habits

Sleep: Direct and disruptive at full doses. The 8–12 hour duration means any dose taken after midday displaces sleep onset, and the released compound also alters sleep architecture directly, reducing slow-wave and REM (rapid eye movement, the dreaming stage of sleep) continuity on the night of dosing. The interaction is largely avoidable through morning dosing and clearing the following day. At low doses the interaction is smaller but persists: afternoon low doses reliably delay sleep onset, and taking them on waking removes most of the effect. Because there is no dependence, the sleep cost is entirely a function of timing rather than an unavoidable feature.
Nutrition: Indirect. Absorption is faster on an empty stomach, and the clinical protocols use a light breakfast or a short fast before dosing largely to reduce nausea, which is common in the first hour. There is no evidence of nutrient depletion. Two dietary considerations do matter: serotonergic supplements taken as part of a nutrition protocol — 5-HTP, L-Tryptophan, St. John’s wort — add serotonergic load or blunt the response and are worth separating by at least a week, and high-dose caffeine on a dosing day compounds the cardiovascular and anxiety effects. No particular dietary pattern has been shown to modify response.
Exercise: Blunting in one direction, additive risk in the other. Strenuous exercise during the active period adds cardiovascular load to an already elevated blood pressure and heart rate and is best avoided for the full duration; impaired coordination and altered risk perception make anything technical or load-bearing genuinely hazardous. In the other direction, the plasticity-promoting mechanism proposed for this class overlaps with the mechanism proposed for aerobic exercise, and there is a plausible but entirely untested argument that pairing them could be additive. Light walking is compatible with a session and is used in some clinical protocols; training resumes the following day.
Stress management: Direct and potentiating in both directions. The released compound acutely raises cortisol and prolactin, so the physiological signature during a session resembles a stress response even when the subjective experience is positive. The trial protocols treat this as the reason preparation and supervision are structural rather than optional: an unmanaged stress response is the mechanism by which a session becomes a difficult one. Practically, this means established stress-regulation practice before a session rather than during it — the clinical protocols use breathwork and body-focused attention as the standard in-session response to rising anxiety, and prior familiarity with those techniques is what makes them usable when they are needed. Meditation practice and psychedelic experience appear to be mutually reinforcing in the observational literature, though the direction of that relationship is not established.

Monitoring Protocol & Defining Success

Baseline testing serves two distinct purposes here: establishing that the cardiovascular and hepatic systems can tolerate a compound that reliably raises blood pressure for 8–12 hours, and creating a documented starting point against which the theoretical cumulative risks — particularly heart valve status — can later be compared. The full baseline panel below is appropriate before a first full dose; before starting a low-dose regimen, blood pressure, resting heart rate, and a metabolic and liver panel are the minimum.

Ongoing monitoring follows a defined cadence rather than an ad hoc one: blood pressure and resting heart rate before and 2 hours after each dose, a repeat blood panel at 3 months after starting any repeated regimen, then every 6–12 months while use continues, and a repeat echocardiogram at 24 months for anyone dosing more often than monthly.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
Seated blood pressure	105–120 / 65–80 mmHg	Determines tolerable dose ceiling	Conventional threshold for concern is 140/90 mmHg; a functional target is tighter. Average three readings taken on separate days, seated and rested 5 minutes. Repeat 2 hours post-dose to capture the peak rise.
Resting heart rate	50–70 bpm	Baseline for the reliable acute rise	Conventional normal spans 60–100 bpm, so the functional target sits well below the conventional ceiling. Measure on waking before rising. Wearable overnight averages are more informative than a single clinic reading.
Echocardiogram, valve morphology	No regurgitation beyond trace at any valve	Documents valve status before cumulative 5-HT2B exposure	Conventional practice does not screen asymptomatic adults at all; this is a functional-medicine precaution specific to compounds acting at the serotonin 2B receptor. Only warranted before regimens exceeding roughly monthly dosing. Repeat at 24 months.
Electrocardiogram, QTc interval	< 440 ms men, < 450 ms women	Screens for the rhythm vulnerability that computational models flag	Conventional upper limits are 450 and 470 ms. QTc is the corrected interval measuring how long the heart takes to reset between beats; relevant because hERG channel inhibition was predicted for several analogues. Best paired with the echocardiogram in a single visit.
ALT and AST	ALT 10–26 U/L women, 10–30 U/L men; AST 10–26 U/L	Confirms hepatic capacity to clear the released compound	ALT and AST are liver enzymes that rise when liver cells are stressed. Conventional upper limits run to 40–55 U/L, well above the functional range. Fasting preferred; avoid within 48 hours of intense exercise, which raises AST independently.
Complete blood count	Haemoglobin 13.5–15.0 g/dL men, 12.5–14.5 women; platelets 200–300 ×10⁹/L	Addresses the hematotoxicity signal predicted for 1P-LSD and 1B-LSD	A complete blood count measures the cellular components of blood. Conventional laboratory ranges are considerably wider — haemoglobin 13.5–17.5 g/dL men and 12.0–15.5 g/dL women, platelets 150–450 ×10⁹/L. Purely precautionary — the signal is computational, not observed. Non-fasting is acceptable.
eGFR with creatinine and cystatin C	> 90 mL/min/1.73 m²	Confirms clearance of downstream metabolites	eGFR is the estimated glomerular filtration rate, a measure of kidney filtering capacity. Conventional concern begins below 60. Cystatin C-based estimation is more reliable in people with high muscle mass. Avoid creatine supplementation for 2 weeks before testing.
hs-CRP	< 0.5 mg/L	Baseline for the speculative anti-inflammatory claim	hs-CRP is high-sensitivity C-reactive protein, a blood marker of low-grade inflammation. Conventional low-risk cutoff is under 3.0 mg/L. Invalid within 2 weeks of any infection or injury.
Prolactin	Men < 15 ng/mL; women < 20 ng/mL	Detects sustained endocrine effect of ergoline exposure	Ergoline compounds act on dopamine pathways that regulate prolactin, and the released compound raises it acutely. Conventional upper limits run to roughly 18 ng/mL in men and 30 ng/mL in non-pregnant women, so the functional target is appreciably tighter. Highly time-dependent — draw between 08:00 and 10:00, at least 1 hour after waking, avoiding nipple stimulation or exercise beforehand.
CYP2D6 genotype	Normal metaboliser (two functional copies)	Predicts exposure and duration at a given dose	CYP2D6 is the liver enzyme performing much of the breakdown of the released compound. One-time test with no range to track. Poor metaboliser status warrants a proportionally lower starting dose.

Qualitative markers are more informative than any laboratory value for judging whether a regimen is working, and the protocols that track them record on a fixed schedule rather than by recall:

Sleep quality and continuity: Tracked on off-days rather than dosing days. Sleep that has not normalised by the second off-day indicates the schedule is too dense.
Daytime energy and subjective vigour: The effect most reliably detected in controlled low-dose studies, and therefore the most useful single subjective marker.
Cognitive clarity and working memory in real tasks: Recorded against actual work output rather than impression, since the low-dose literature identifies cognitive impairment as a common side effect and self-assessment in this class is known to be optimistic.
Anxiety and mood, scored rather than described: A brief validated self-report scale completed weekly gives a usable trajectory; impressionistic recall does not, and the expectancy effect documented in this literature makes unblinded impression particularly unreliable.
Emotional reactivity and interpersonal friction: Reported by someone else where possible, because irritability and blunting are more visible externally than internally.
Absence of between-dose perceptual disturbance: Explicitly checked rather than assumed, since persisting visual phenomena are the earliest signal warranting discontinuation.

Success for a low-dose regimen is a measurable and sustained improvement in scored mood or vigour over 8–12 weeks with no rise in resting blood pressure, no sleep degradation on off-days, and no perceptual disturbance between doses. Success for the full-dose model is improvement in the target symptom persisting weeks after a session, not the quality of the session itself. Absence of any of these by the defined endpoint is itself a result, and the regimens described here treat it as a stopping point rather than as grounds for escalation.

Emerging Research

First-in-human trial of a short-acting analogue: The Liechti group at University Hospital Basel is running an open dose-escalation phase followed by a randomised, double-blind, placebo-controlled crossover comparing DDH-LSD against the parent compound and placebo in 24 healthy volunteers (NCT07309471, recruiting since March 2026, primary completion estimated July 2028). DDH-LSD was designed for faster metabolism and therefore a shorter experience; the primary endpoints are the effective dose and the comparison of elimination half-life and duration against a 100 µg reference dose. This is the first controlled human study of any novel LSD analogue and will be the first hard data on whether the duration problem — the practical obstacle to supervised use at scale — is solvable within this chemical family.
Non-hallucinogenic congener 2-Br-LSD: The preclinical case rests on Lewis et al., 2023, whose author list includes staff of BetterLife Pharma, the company developing the compound. Early-phase human safety work has been announced by the sponsor, but no registered ClinicalTrials.gov record for 2-Br-LSD was located, so the trial details cannot be independently verified here. The absence of a public registry entry is itself relevant to how the results should be weighed when they appear.
Plasticity-promoting analogue (+)-JRT: Tuck et al., 2025 reported the design and total synthesis of an LSD analogue that promotes cortical spine growth with reduced hallucinogenic potential and without worsening psychosis-relevant gene expression, positioning it explicitly for populations in whom psychedelics are contraindicated. The author list includes Delix Therapeutics personnel. No human trial has been registered.
Parent-compound benchmark trials: Two Phase 3 programmes are testing DT120, the tartrate salt of the parent compound previously designated MM120, in generalised anxiety disorder (NCT06741228, 214 participants, primary endpoint change in the Hamilton Anxiety Rating Scale at 12 weeks) and in major depressive disorder (NCT06941844, 149 participants), both sponsored by Definium Therapeutics. These do not test any analogue, but they set the efficacy and safety benchmark that every prodrug analogue inherits by conversion and that every non-hallucinogenic analogue must eventually be measured against.
Evidence that could weaken the case: Three recent syntheses run against the optimistic reading. Chen et al., 2025 found the entire non-hallucinogenic literature amounts to five animal studies and one case report. Jurowski et al., 2026 produced computational toxicity flags for pulmonary, hematological, genotoxic, and cardiac-rhythm endpoints across five common prodrug analogues. Eskinazi et al., 2026 quantified the mania and hypomania risk that defines the exclusion criteria for this class.
Unresolved question with the largest longevity stake: Xu et al., 2026 pooled seventeen studies on 5-HT2B-mediated valve disease and found that the parent compound binds the receptor with high affinity and drives the fibrotic signalling implicated in valve damage, but that no clinical case of valve disease attributed to it has ever been reported. No prospective echocardiographic study of frequent psychedelic users has been published, so the concern that shapes the entire long-term risk picture rests on mechanism and class analogy alone. A cohort study with serial imaging would settle it in either direction, and its absence is the single largest gap in the safety literature for anyone considering years rather than sessions.
Second unresolved question, on the benefit side: Whether the therapeutic effect survives removal of the hallucinatory experience is the question on which the commercial value of the entire non-hallucinogenic branch depends, and it will be answered only by a controlled human trial that none of the interested parties has yet registered.

Conclusion

LSD analogues are two very different things sharing a chemical family name. The larger group are shells the body strips away to release ordinary LSD, and human measurement shows this release is near complete. Their contribution is delivery: they make a well-studied molecule obtainable and inherit its effects, risks, and doses. The smaller group is engineered in the opposite direction, keeping the brain-remodelling effects while removing the visions, and almost all of it is still in animals.

The strongest documented benefit of the first group is about drug behaviour, not health outcomes. Everything past that — easing of anxiety and low mood, less drinking, lifted mood and dulled pain at tiny doses, headache prevention, a version that looks gentler on heart valves — rests on a chain running from a few controlled studies through small uncontrolled reports to computer models, weakening at every link. The harms belong mostly to the released molecule: sharp rises in blood pressure and heart rate, nausea and headache, acute fear, confusion, and impaired judgement, and the possibility of tipping susceptible people into mania. Unregulated manufacture adds a harm of its own: what is in a product is often not what the label says.

Much of the most encouraging work on the engineered compounds comes from teams including employees of the developing firms, and the parent-molecule trials are company-funded throughout. For an audience able to screen itself, verify what it has, and stop on a defined endpoint, the evidence remains early, thin, and commercially entangled.

Top - Benefits - Risks - Protocol

LSD Analogues for Health & Longevity

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

High 🟩 🟩 🟩

Near-complete and predictable conversion to the parent compound

Medium 🟩 🟩

Reduction of anxiety symptoms

Reduction of depressive symptoms

Reduction of problem alcohol and substance use

Mood elevation and increased vigour at low doses ⚠️ Conflicted

Low 🟩

Cluster headache prevention with the non-hallucinogenic congener

Receptor profile that avoids the heart-valve liability

Structural neuroplasticity without hallucinogenic effect

Choice of onset and duration profile

Raised pain tolerance at low doses ⚠️ Conflicted

Speculative 🟨

Sustained regimens without tolerance build-up

Effects on cognitive and functional ageing

Immune and inflammatory modulation at low doses

Cognitive performance and creativity at low doses

Benefit-Modifying Factors

Potential Risks & Side Effects

High 🟥 🟥 🟥

Acute anxiety, panic, and confusion

Acute rise in blood pressure and heart rate

Nausea, headache, dizziness, and fatigue

Impaired judgement, coordination, and accident risk

Dose uncertainty from unregulated manufacture

Medium 🟥 🟥

Precipitation of mania, hypomania, or psychosis

Worsening depression and emergent suicidality

Rapid tolerance with repeated dosing

Next-day impairment and sleep disruption

Low 🟥

Hallucinogen persisting perception disorder ⚠️ Conflicted

Cardiac valve fibrosis with chronic exposure

Predicted organ toxicity signals from computational modelling

Speculative 🟨

Impurity and by-product exposure from grey-market synthesis

Long-term receptor regulation from sustained low-dose use

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion